Cadrenal Therapeutics Inc <CVKD.OQ> expected to post a loss of $1.60 a share - Earnings Preview
Cadrenal Therapeutics Inc CVKD.OQ CVKD.O is expected to show no change in quarterly revenue when it reports results on August 7 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Cadrenal Therapeutics Inc is for a loss of $1.60 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cadrenal Therapeutics Inc is $32.00, about 72.5% above its last closing price of $8.81
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.13 | -1.64 | -2.09 | Missed | -27.4 |
Dec. 31 2025 | -1.41 | -1.71 | -2.74 | Missed | -59.9 |
Sep. 30 2024 | -1.94 | -1.93 | -2.18 | Missed | -13.1 |
Jun. 30 2024 | -1.80 | -1.27 | -2.25 | Missed | -76.5 |
Mar. 31 2024 | -1.05 | -1.50 | Missed | -42.9 | |
Dec. 31 2023 | -1.27 | -1.27 | -0.75 | Beat | 41.2 |
This summary was machine generated August 5 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
